한글목차

세계의 인플루엔자 백신 시장 규모는 2033년까지 10.5%의 CAGR로 성장할 것으로 예측되고 있습니다.

인플루엔자의 세계 유행은 증가하고 있습니다. 만연하는 감염을 막는 가장 효과적인 방법은 백신 접종입니다. 세계의 인구 고령화에 수반하여 인플루엔자로 이환하기 쉬워지며, 인플루엔자 백신의 수요가 높아지고 있습니다. 인플루엔자에 대한 의식의 향상, 헬스케어 서비스의 향상, 선진국에서의 높은 출생률 등이 예측 기간 중 인플루엔자 백신 수요의 증가에 기여하고 있습니다.

세계의 인플루엔자 백신 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모의 추이·예측, 각종 구분·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 촉진요인
  • 시장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter's Five Forces 분석
• PEST 분석

제4장 인플루엔자 백신 시장 분석 : 백신 유형별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모 추산·예측
• 4가
• 3가

제5장 인플루엔자 백신 시장 분석 : 최종사용자별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모 추산·예측
• 전문 클리닉
• 병원
• 기타

제6장 인플루엔자 백신 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추산·예측

제7장 북미의 인플루엔자 백신 시장 분석

제8장 유럽의 인플루엔자 백신 시장 분석

제9장 아시아태평양의 인플루엔자 백신 시장 분석

제10장 라틴아메리카의 인플루엔자 백신 시장 분석

제11장 중동 및 아프리카의 인플루엔자 백신 시장 분석

제12장 기업 개요

• CSL
• Emergent BioSolutions Inc.
• GSK plc
• Pfizer Inc.
• Sanofi
• AstraZeneca
• SINOVAC
• Viatris Inc.(Mylan)
• Abbott Laboratories
• BIKEN Co., Ltd.

제13장 결론·제안

• Visiongain으로부터의 결론
• 시장 참여 기업에 대한 제안

영문목차

The global Influenza Vaccines market is projected to grow at a CAGR of 10.5% by 2033.

“The Influenza Vaccines Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The global prevalence of influenza is on the rise. The most effective method of averting the widespread infection is through vaccination. As the global population ages, individuals become more susceptible to influenza, which increases the demand for influenza vaccines. Increasing awareness of influenza, the improvement of healthcare services, and high birth rates in developed nations will all contribute to increased demand for current and new influenza vaccines during the forecast period. As a result, the influenza vaccine sector exhibits substantial growth prospects and robust revenue generation. Vaccination is a stressful experience, especially for children; therefore, an organisation that provides a non-stressful vaccine stands to gain substantial benefits.

What Questions Should You Ask before Buying a Market Research Report?

• How is the influenza vaccines market evolving?
• What is driving and restraining the influenza vaccines market?
• How will each influenza vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each influenza vaccines submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading influenza vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the influenza vaccines projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of

influenza vaccines projects taking place now and over the next 10 years?

• Is there a greater need for product commercialisation to further scale the influenza vaccines market?
• Where is the influenza vaccines market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the influenza vaccines market today, and over the next 10 years:

• Our 192-page report provides 77 tables and 116 charts/graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the influenza vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Vaccine Type

• Quadrivalent
• Trivalent

End-users

• Specialty Clinics
• Hospitals
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Influenza Vaccines Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

Overall world revenue for Influenza Vaccines Market, 2023 to 2033 in terms of value the market will surpass US$6,600.0million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Influenza Vaccines Market, 2023 to 2033 report help you?

In summary, our 190+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Influenza Vaccines Market 2023 to 2033, with forecasts for vaccine type and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 21 key national markets - See forecasts for the Influenza Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Influenza Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Influenza Vaccines Market 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Influenza Vaccines Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Growing Elderly Population Driving Industry Growth
    • 3.2.1.2 Growing Interest in Vaccine Development
    • 3.2.1.3 High Prevalence of Infectious Diseases Anticipated to Spur Industry Growth
    • 3.2.1.4 Increase in Government Focus on Immunization Programs
    • 3.2.1.5 Paediatric Influenza Vaccines Boosting Industry Growth
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Inadequate Reimbursement Coverage Likely to Challenge Industry Growth
    • 3.2.2.2 Longer Timelines for Vaccine Development Projected to Hamper Market Growth
    • 3.2.2.3 Supply Chain Constraints
    • 3.2.2.4 Storage and Handling Challenges
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Emerging Economies
    • 3.2.3.2 Personalized Vaccination Strategies
    • 3.2.3.3 Pandemic Preparedness and Stockpiling
    • 3.2.3.4 Education and Public Awareness Campaigns
    • 3.2.3.5 Strong R&D Pipeline
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Supplier Power
  • 3.4.2 Buyer Power
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis
  • 3.5.1 Political Factors
  • 3.5.2 Economic Factors
  • 3.5.3 Social Factors
  • 3.5.4 Technological Factors

4 Influenza Vaccines Market Analysis by Vaccine Type

• 4.1 Key Findings
• 4.2 Vaccine Type Segment: Market Attractiveness Index
• 4.3 Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
• 4.4 Quadrivalent
  • 4.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
• 4.5 Trivalent
  • 4.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)

5 Influenza Vaccines Market Analysis by End-users

• 5.1 Key Findings
• 5.2 End-users Segment: Market Attractiveness Index
• 5.3 Influenza Vaccines Market Size Estimation and Forecast by End-users
• 5.4 Specialty Clinics
  • 5.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 Hospitals
  • 5.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)
• 5.6 Others
  • 5.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Influenza Vaccines Market Analysis by Region

• 6.1 Key Findings
• 6.2 Regional Market Size Estimation and Forecast

7 North America Influenza Vaccines Market Analysis

• 7.1 Key Findings
• 7.2 North America Influenza Vaccines Market Attractiveness Index
• 7.3 North America Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 7.4 North America Influenza Vaccines Market Size Estimation and Forecast by Country
• 7.5 North America Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
• 7.6 North America Influenza Vaccines Market Size Estimation and Forecast by End-users
• 7.7 U.S. Influenza Vaccines Market Analysis
• 7.8 Canada Influenza Vaccines Market Analysis

8 Europe Influenza Vaccines Market Analysis

• 8.1 Key Findings
• 8.2 Europe Influenza Vaccines Market Attractiveness Index
• 8.3 Europe Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 8.4 Europe Influenza Vaccines Market Size Estimation and Forecast by Country
• 8.5 Europe Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
• 8.6 Europe Influenza Vaccines Market Size Estimation and Forecast by End-users
• 8.7 Germany Influenza Vaccines Market Analysis
• 8.8 UK Influenza Vaccines Market Analysis
• 8.9 France Influenza Vaccines Market Analysis
• 8.10 Italy Influenza Vaccines Market Analysis
• 8.11 Spain Influenza Vaccines Market Analysis
• 8.12 Russia Influenza Vaccines Market Analysis
• 8.13 Rest of Europe Influenza Vaccines Market Analysis

9 Asia Pacific Influenza Vaccines Market Analysis

• 9.1 Key Findings
• 9.2 Asia Pacific Influenza Vaccines Market Attractiveness Index
• 9.3 Asia Pacific Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 9.4 Asia Pacific Influenza Vaccines Market Size Estimation and Forecast by Country
• 9.5 Asia Pacific Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
• 9.6 Asia Pacific Influenza Vaccines Market Size Estimation and Forecast by End-users
• 9.7 Japan Influenza Vaccines Market Analysis
• 9.8 China Influenza Vaccines Market Analysis
• 9.9 India Influenza Vaccines Market Analysis
• 9.10 Australia Influenza Vaccines Market Analysis
• 9.11 South Korea Influenza Vaccines Market Analysis
• 9.12 South-East Asia Influenza Vaccines Market Analysis
• 9.13 Rest of Asia Pacific Influenza Vaccines Market Analysis

10 Latin America Influenza Vaccines Market Analysis

• 10.1 Key Findings
• 10.2 Latin America Influenza Vaccines Market Attractiveness Index
• 10.3 Latin America Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 10.4 Latin America Influenza Vaccines Market Size Estimation and Forecast by Country
• 10.5 Latin America Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
• 10.6 Latin America Influenza Vaccines Market Size Estimation and Forecast by End-users
• 10.7 Brazil Influenza Vaccines Market Analysis
• 10.8 Mexico Influenza Vaccines Market Analysis
• 10.9 Rest of Latin America Influenza Vaccines Market Analysis

11 MEA Influenza Vaccines Market Analysis

• 11.1 Key Findings
• 11.2 MEA Influenza Vaccines Market Attractiveness Index
• 11.3 MEA Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 11.4 MEA Influenza Vaccines Market Size Estimation and Forecast by Country
• 11.5 MEA Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
• 11.6 MEA Influenza Vaccines Market Size Estimation and Forecast by End-users
• 11.7 GCC Influenza Vaccines Market Analysis
• 11.8 South Africa Influenza Vaccines Market Analysis
• 11.9 Rest of MEA Influenza Vaccines Market Analysis

12 Company Profiles

• 12.1 CSL
  • 12.1.1 Company Snapshot
  • 12.1.2 Company Overview
  • 12.1.3 Financial Analysis
    • 12.1.3.1 Net Revenue, 2015-2022
    • 12.1.3.2 R&D, 2015-2022
    • 12.1.3.3 Regional Market Shares, 2022
  • 12.1.4 Product Benchmarking
  • 12.1.5 Strategic Outlook
• 12.2 Emergent BioSolutions Inc.
  • 12.2.1 Company Snapshot
  • 12.2.2 Company Overview
  • 12.2.3 Financial Analysis
    • 12.2.3.1 Net Revenue, 2015-2022
    • 12.2.3.2 R&D, 2015-2022
  • 12.2.4 Product Benchmarking
• 12.3 GSK plc
  • 12.3.1 Company Snapshot
  • 12.3.2 Company Overview
  • 12.3.3 Financial Analysis
    • 12.3.3.1 Net Revenue, 2015-2022
    • 12.3.3.2 R&D, 2015-2022
    • 12.3.3.3 Regional Market Shares, 2022
  • 12.3.4 Product Benchmarking
  • 12.3.5 Strategic Outlook
• 12.4 Pfizer Inc.
  • 12.4.1 Company Snapshot
  • 12.4.2 Company Overview
  • 12.4.3 Financial Analysis
    • 12.4.3.1 Net Revenue, 2015-2022
    • 12.4.3.2 R&D, 2015-2022
  • 12.4.4 Product Benchmarking
  • 12.4.5 Strategic Outlook
• 12.5 Sanofi
  • 12.5.1 Company Snapshot
  • 12.5.2 Company Overview
  • 12.5.3 Financial Analysis
    • 12.5.3.1 Net Revenue, 2015-2022
    • 12.5.3.2 R&D, 2015-2022
    • 12.5.3.3 Regional Market Shares, 2022
  • 12.5.4 Product Benchmarking
  • 12.5.5 Strategic Outlook
• 12.6 AstraZeneca
  • 12.6.1 Company Snapshot
  • 12.6.2 Company Overview
  • 12.6.3 Financial Analysis
    • 12.6.3.1 Net Revenue, 2015-2022
    • 12.6.3.2 R&D, 2015-2022
    • 12.6.3.3 Regional Market Shares, 2022
  • 12.6.4 Product Benchmarking
  • 12.6.5 Strategic Outlook
• 12.7 SINOVAC
  • 12.7.1 Company Snapshot
  • 12.7.2 Company Overview
  • 12.7.3 Financial Analysis
    • 12.7.3.1 Net Revenue, 2015-2022
    • 12.7.3.2 R&D, 2015-2022
  • 12.7.4 Product Benchmarking
  • 12.7.5 Strategic Outlook
• 12.8 Viatris Inc. (Mylan)
  • 12.8.1 Company Snapshot
  • 12.8.2 Company Overview
  • 12.8.3 Financial Analysis
    • 12.8.3.1 Net Revenue, 2015-2022
    • 12.8.3.2 Regional Market Shares, 2022
    • 12.8.3.3 R&D, 2015-2022
  • 12.8.4 Product Benchmarking
• 12.9 Abbott Laboratories
  • 12.9.1 Company Snapshot
  • 12.9.2 Company Overview
  • 12.9.3 Financial Analysis
    • 12.9.3.1 Net Revenue, 2015-2022
    • 12.9.3.2 Regional Market Shares, 2022
    • 12.9.3.3 R&D, 2015-2022
  • 12.9.4 Product Benchmarking
• 12.10 BIKEN Co., Ltd.
  • 12.10.1 Company Snapshot
  • 12.10.2 Company Overview
  • 12.10.3 Product Benchmarking
  • 12.10.4 Strategic Outlook

13 Conclusion and Recommendations

• 13.1 Concluding Remarks from Visiongain
• 13.2 Recommendations for Market Players